(Reuters) -British drugmaker GSK said on Monday Emma Walmsley will step down as CEO after nine years in the role and will be replaced by insider Luke Miels in January.

Since taking over in 2017, Walmsley has returned GSK to growth, with a focus on cancer and infectious diseases to counter a combination of patent expiries and declining revenue from its best-selling medicines by 2030.

“2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe the right moment for new leadership,” Walmsley said.

Miels will be tasked with leading a new phase of the company and delivering GSK’s sales target of more than 40 billion pounds ($53.76 billion) by 2031.

Miels, 50, joined GSK in 2017 and is currently the drugmaker’s chief commercial officer, overseeing the company’s glo

See Full Page